{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:04:48Z","timestamp":1783191888580,"version":"3.54.6"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022411","name":"University of Hong Kong-Shenzhen Hospital","doi-asserted-by":"publisher","award":["HKUSZH2026B014"],"award-info":[{"award-number":["HKUSZH2026B014"]}],"id":[{"id":"10.13039\/501100022411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022411","name":"University of Hong Kong-Shenzhen Hospital","doi-asserted-by":"publisher","award":["HKUSZH202207002"],"award-info":[{"award-number":["HKUSZH202207002"]}],"id":[{"id":"10.13039\/501100022411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The management of extensively drug-resistant (XDR)\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (CRAB) in deep-seated infections remains a critical challenge, particularly when compounded by severe host comorbidities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report the case of a 63-year-old male with Stage IV rectal squamous cell carcinoma and Kennedy\u2019s disease (spinal and bulbar muscular atrophy) who developed concurrent pulmonary and intra-abdominal infections with CRAB and carbapenem-resistant\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (CRPA) following emergent colorectal surgery. After the failure of an initial salvage regimen comprising polymyxin B, minocycline, and ampicillin-sulbactam, therapy was escalated to sulbactam-durlobactam combined with imipenem-cilastatin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Microbiological cure was achieved within 14 days, confirmed by the sterilization of both bronchoalveolar lavage fluid and peritoneal drainage cultures. Despite successful source control and infection eradication, the patient could not be weaned from mechanical ventilation. The convergence of critical illness polyneuropathy\/myopathy (CIP\/CIM), pre-existing neuromuscular degeneration, and malignant cachexia resulted in fatal multiple organ dysfunction syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests the potential utility of sulbactam-durlobactam in combination with a carbapenem for complicated intra-abdominal infection (cIAI) caused by CRAB, highlighting a successful microbiological outcome. However, it also underscores that microbiological eradication does not invariably translate to clinical survival when overwhelming host factors and irreversible comorbidities dictate the ultimate prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1837081","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:26:56Z","timestamp":1778819216000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Microbiological eradication of XDR Acinetobacter baumannii intra-abdominal infection using sulbactam-durobactam: clinical and microbiological outcomes amidst irreversible host comorbidities"],"prefix":"10.3389","volume":"13","author":[{"given":"Lei","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Intensive Care Unit, The University of Hong Kong - Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieli","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Hong Kong - Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waiming","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The University of Hong Kong - Shenzhen Hospital","place":["Shenzhen, China"]},{"name":"Critical Care Medicine Unit, LKS Faculty of Medicine, The University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The University of Hong Kong - Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The University of Hong Kong - Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The University of Hong Kong - Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.","volume":"399","year":"2022","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.3390\/ijms26146905","article-title":"Antibiotic therapy duration for multidrug-resistant gram-negative bacterial infections: an evidence-based review.","volume":"26","author":"Marino","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of Carbapenem-resistant Acinetobacter baumannii among patients from different global regions.","volume":"78","author":"Wang","year":"2024","journal-title":"Clin Infect Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of acinetobacter infections: a century of challenges.","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"dlaf096","DOI":"10.1093\/jacamr\/dlaf096","article-title":"Clinical efficacy, safety and pharmacokinetics of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: a systematic review.","volume":"7","author":"Alarcia-Lacalle","year":"2025","journal-title":"JAC Antimicrob Resist."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e077292","DOI":"10.1136\/bmj-2023-077292","article-title":"Intensive care unit acquired weakness and physical rehabilitation in the ICU.","volume":"388","author":"Hiser","year":"2025","journal-title":"BMJ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101260","DOI":"10.1016\/j.mam.2024.101260","article-title":"Cancer-associated muscle weakness - from triggers to molecular mechanisms.","volume":"97","author":"Shorter","year":"2024","journal-title":"Mol Aspects Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/cid\/ciae346","article-title":"2024 clinical practice guideline update by the infectious diseases society of America on Complicated intra-abdominal infections: risk assessment, diagnostic imaging, and microbiological evaluation in adults, children, and pregnant people.","volume":"79","author":"Bonomo","year":"2024","journal-title":"Clin Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1038\/s41467-025-58772-9","article-title":"Genomic epidemiology and phylodynamics of Acinetobacter baumannii bloodstream isolates in China.","volume":"16","author":"Luo","year":"2025","journal-title":"Nat Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0169823","DOI":"10.1128\/aac.01698-23","article-title":"Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK).","volume":"68","author":"Miller","year":"2024","journal-title":"Antimicrob Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e02534-19","DOI":"10.1128\/AAC.02534-19","article-title":"In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii- calcoaceticus complex isolates collected globally in 2016 and 2017.","volume":"64","author":"McLeod","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-lactamase inhibitor combinations.","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00159-19","DOI":"10.1128\/mBio.00159-19","article-title":"Targeting multidrug-resistant acinetobacter spp.: sulbactam and the diazabicyclooctenone \u03b2-Lactamase inhibitor ETX2514 as a novel therapeutic agent.","volume":"10","author":"Barnes","year":"2019","journal-title":"mBio"},{"key":"B17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","article-title":"Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options.","volume":"11","author":"Bartal","year":"2022","journal-title":"Infect Dis Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40265-024-02104-6","article-title":"Treatment approaches for carbapenem-resistant Acinetobacter baumannii infections.","volume":"85","author":"Iovleva","year":"2025","journal-title":"Drugs."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0383623","DOI":"10.1128\/spectrum.03836-23","article-title":"In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations.","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol Spectr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00134-020-05944-4","article-title":"ICU-acquired weakness.","volume":"46","author":"Vanhorebeek","year":"2020","journal-title":"Intensive Care Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1837081\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:26:58Z","timestamp":1778819218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1837081\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1837081"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1837081","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1837081"}}